ArticleFrontiers in public health2025
Time to first dose of measles-containing vaccine and associated factors among infants in Ethiopia: a survival analysis from performance monitoring for action data.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Measles challenges: global resurgence and factors affecting eradication.Italian journal of pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The measles-containing vaccine (MCV) is a live attenuated vaccine that helps to develop lifelong immunity, and it prevents measles outbreak when administered at the right time in measles-endemic areas. Many infants received the initial dose of the measles vaccine later than the ideal time frame, and significant others missed the vaccination, causing a recurrent measles outbreak in Ethiopia. This study assessed the time to the first dose of a measles-containing vaccine and associated factors among infants in Ethiopia. Methods: A cohort of 1,770 mother-infant pairs was analysed using data from the performance monitoring for action Ethiopia dataset. Cohort-2 Ethiopian data set was collected in Addis Ababa, Amhara, Oromia and SNNP regions between between November 2021 and August 2023. The key independent variables were socio-demographic characteristics, maternal health service utilization, and pregnancy intention. Multiple imputation was used to handle missing data. Survival analysis was conducted using R programming language version 4.4.1. Multicollinearity was assessed using Generalized variance inflation factors (GVIF), and model fit was evaluated using concordance index and overall model significance. Results: Among 1,770 infants followed, only 27% were vaccinated timely, within 9-10 months of age (survival probability = 0.73), and 53.4% had not yet received MCV1 at 12 months of age. The hazard of receiving the first dose of measles vaccine (MCV1) was 35% lower among infants from pregnancies that were not desired at all (AHR = 0.65, 95% CI: 0.46-0.93) and 21% lower among those infants from pregnancies that were initially undesired but later became wanted (AHR = 0.79, 95% CI: 0.65-0.96), compared to infants from pregnancies that were desired from the beginning. Conclusion: Despite progress in the uptake of the first dose of measles vaccine, timely vaccination in Ethiopia is still low, and many infants in Ethiopia miss the immunization. Institutional delivery, maternal intention regarding pregnancy, religion, and wealth quantile were key predictors of the timeliness of the first dose of measles vaccine. Interventions encouraging institutional deliveries, supporting unintended pregnancy, working with religious leaders, and conducting continuous outreach to immunization services are necessary to improve the timely uptake of the first dose of measles vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.